Bausch Health Companies Inc. (TSX:BHC)
Canada
· Delayed Price · Currency is CAD 6.51
-0.18 (-2.69%)
May 13, 2025, 12:58 PM EDT
Revenue by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Bausch + Lomb | 4.79B |
Log In |
Log In |
Log In |
Log In |
| Bausch + Lomb Growth | 15.56% |
Log In |
Log In |
Log In |
Log In |
| Salix | 2.33B |
Log In |
Log In |
Log In |
Log In |
| Salix Growth | 3.69% |
Log In |
Log In |
Log In |
Log In |
| Diversified Products | 950.00M |
Log In |
Log In |
Log In |
Log In |
| Diversified Products Growth | 0.74% |
Log In |
Log In |
Log In |
Log In |
| Ortho Dermatologies | - |
Log In |
Log In |
Log In |
Log In |
| Ortho Dermatologies Growth | - |
Log In |
Log In |
Log In |
Log In |
| International Rx | 1.11B |
Log In |
Log In |
Log In |
Log In |
| International Rx Growth | 3.73% |
Log In |
Log In |
Log In |
Log In |
| Solta Medical | 440.00M |
Log In |
Log In |
Log In |
Log In |
| Solta Medical Growth | 26.80% |
Log In |
Log In |
Log In |
Log In |
EBIT by Product
Fiscal year is January - December.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Bausch + Lomb Segment Profit | 1.11B |
Log In |
Log In |
Log In |
Log In |
| Bausch + Lomb Segment Profit Growth | 13.06% |
Log In |
Log In |
Log In |
Log In |
| Salix Segment Profit | 1.60B |
Log In |
Log In |
Log In |
Log In |
| Salix Segment Profit Growth | 3.49% |
Log In |
Log In |
Log In |
Log In |
| Diversified Products Segment Profit | 626.00M |
Log In |
Log In |
Log In |
Log In |
| Diversified Products Segment Profit Growth | 6.83% |
Log In |
Log In |
Log In |
Log In |
| Ortho Dermatologies Segment Profit | - |
Log In |
Log In |
Log In |
Log In |
| Ortho Dermatologies Segment Profit Growth | - |
Log In |
Log In |
Log In |
Log In |
| International Rx Segment Profit | 376.00M |
Log In |
Log In |
Log In |
Log In |
| International Rx Segment Profit Growth | 12.24% |
Log In |
Log In |
Log In |
Log In |
| Solta Medical Segment Profit | 213.00M |
Log In |
Log In |
Log In |
Log In |
| Solta Medical Segment Profit Growth | 32.30% |
Log In |
Log In |
Log In |
Log In |